Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics

Companies Collaborate in Their Aim to Accelerate Accurate Diagnosis of Cancer for Patients in China

SANTA CLARA, Calif., and GUANGZHOU, China – Agilent Technologies Inc. (NYSE: A) and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system.

Agilent is the leading provider of target enrichment for next-generation DNA sequencing. Target enrichment saves researchers time and resources by enabling them to focus on regions of interest rather than looking at the entire genome. Burning Rock is a fast-growing company focused on developing cancer diagnostics based on DNA sequencing.

“As the leader in molecular cancer diagnosis in China, Burning Rock is very pleased to partner with Agilent, a global leader in diagnostics and genomics,” said Yusheng Han, the founder and chief executive officer of Burning Rock. “Collaboration between our two companies wi

< | >